Summary:
Mizuho Securities Analyst, Dr Graig Suvannavejh, joined the 2025 Immuno-Oncology 360º Summit to share an outlook on the IO biotech market, high-level thoughts on the IO space, and public IO company case studies to illustrate the market's perception of what's happening in IO. 

More specifically:

• The current tailwinds working for and headwinds working against investment in biotech
• The increasing specialization of investors and lack of generalist investors 
• The impacts of challenging and/or disappointing readouts after the first wave of checkpoint inhibitors
• Where investors are more positive on biotech, and reasons for optimism in coming pipelines

For more information, visit IO360summit.com